Effectiveness of Non-Animal Chondroitin Sulfate Supplementation in the Treatment of Moderate Knee Osteoarthritis in a Group of Overweight Subjects: A Randomized, Double-Blind, Placebo-Controlled Pilot Study
| Autor: | Maurizio Naso, Mara Nichetti, Milena Anna Faliva, Valentina Braschi, Giancarlo Iannello, Gabriella Peroni, Clara Gasparri, Simone Perna, Niccolò Miraglia, Tariq A. Alalwan, Mariangela Rondanelli, Daniele Spadaccini, Pietro Putignano |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Male obesity Time Factors Knee Joint Anti-Inflammatory Agents Arthritis Pilot Projects Osteoarthritis Overweight 0302 clinical medicine Absorptiometry Photon pain Settore MED/49 - Scienze Tecniche Dietetiche Applicate Adiposity Pain Measurement Nutrition and Dietetics medicine.diagnostic_test Chondroitin Sulfates Osteoarthritis Knee Middle Aged Photon C-Reactive Protein Treatment Outcome Italy Erythrocyte sedimentation rate Female medicine.symptom Inflammation Mediators lcsh:Nutrition. Foods and food supply medicine.medical_specialty WOMAC Visual analogue scale lcsh:TX341-641 Placebo Article knee osteoarthritis non-animal chondroitin sulfate 03 medical and health sciences Double-Blind Method Internal medicine medicine Humans overweight Knee Absorptiometry Inflammation Knee osteoarthritis Non-animal chondroitin sulfate Obesity Pain Aged Biomarkers Quality of Life Recovery of Function Dietary Supplements 030203 arthritis & rheumatology business.industry medicine.disease Confidence interval 030104 developmental biology inflammation business Food Science |
| Zdroj: | Nutrients, Vol 11, Iss 9, p 2027 (2019) Nutrients Volume 11 Issue 9 |
| ISSN: | 2072-6643 |
| Popis: | Osteoarthritis (OA) is the most common form of arthritis in the world and is characterized by pain, various disabilities and loss of quality of life. Chondroitin sulfate (CS) is recommended as first-line therapy. CS of non-animal origin is of great interest for safety and sustainability reasons. This study aims to investigate the anti-inflammatory effects, anti-pain and ability-enhancement of a short-term supplementation with non-animal CS in overweight subjects with OA. In a randomized, double-blind, placebo-controlled pilot study, 60 overweight adults with symptomatic OA were allocated to consume 600 mg of non-animal CS (n = 30) or a placebo (n = 30) daily for 12 consecutive weeks. The assessment of knee-pain, quality of life, related inflammation markers and body composition was performed at 0, 4 and 12 weeks. The Tegner Lysholm Knee Scoring (TLKS) scale of the experimental group showed a statistically significant increase (+10.64 points confidence interval (95% confidence interval (CI) 5.57 15.70 p < 0.01), while the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score decreased (&minus 12.24 points CI 95% &minus 16.01 &minus 8.38 0.01). The results also showed a decrease in the C-reactive protein (CRP) level (&minus 0.14 mg/dL, CI 95% &minus 0.26 0.04 0.01) and erythrocyte sedimentation rate (ESR) level (&minus 5.01 mm/h, CI 95% &minus 9.18 0.84, p < 0.01) as well as the visual analogue scale (VAS) score in both knees. In conclusion, this pilot study demonstrates the effectiveness of non-animal CS supplementation in overweight subjects with knee OA in improving knee function, pain and inflammation markers. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|